Lymphoid cells, both B and T cells circulate in blood vessels and secondary lymphoid organs to ensure the immune response. Chronic inflammation conditions or genomic alteration could modify the behavior of lymphoid cells, inducing proliferation and intracellular pathway modification, resulting in tumor transformation. Despite circulating tumor lymphocytes lose their proliferation capability, they have a high mitosis rate into the germinal centers. Here, transformed lymphocytes establish close crosstalk with the stromal cells and several subtype cells composing the tumor microenvironment, in terms of cytokines, proliferation factors, and extracellular vesicles (EVs) exchange, in order to increase the proliferation rate and the progression of the disease.
The tumor microenvironment plays a pivotal role in supporting tumor growth and transformed cells' survival. Recent data demonstrated that a chronic inflammatory condition persists, involving an innovative way of communication among tumor cells and accessory cells: the release of a class of extracellular vesicles (EVs) named exosomes. Exosomes are small vesicles components of the total circulome, carrying a wide range of molecules, such as proteins, DNA, RNA, miRNAs, and cytokines, based on the cell of origin. In course of the diseases, exosomes contact target cells, near or far, and pour out in these cells their content, modifying phenotype or intracellular pathway, resulting in pro-survival stimuli for tumor cells.
The aim of this Research Topic is to describe how this well-regulated crosstalk between transformed cells and tumor microenvironment improves the progression and survival of the tumor cells, including the role of tumor circulome as a predictor of diagnosis and prognosis, in the field of new molecular drug discovery.
We welcome contributions of different types of articles including original research articles, hypotheses, and theory, as well as reviews and mini-reviews, in particular, the following themes:
• Role of tumor microenvironment in tumor lymphocytes supporting
• Targeting of circulome and exosomes released by lymphoid cells and tumor microenvironment cells for the identification of novel biomarkers
• Perspective in pharmacological targeting of exosomes for diagnosis and treatment of lymphoid cells pathologies.
Lymphoid cells, both B and T cells circulate in blood vessels and secondary lymphoid organs to ensure the immune response. Chronic inflammation conditions or genomic alteration could modify the behavior of lymphoid cells, inducing proliferation and intracellular pathway modification, resulting in tumor transformation. Despite circulating tumor lymphocytes lose their proliferation capability, they have a high mitosis rate into the germinal centers. Here, transformed lymphocytes establish close crosstalk with the stromal cells and several subtype cells composing the tumor microenvironment, in terms of cytokines, proliferation factors, and extracellular vesicles (EVs) exchange, in order to increase the proliferation rate and the progression of the disease.
The tumor microenvironment plays a pivotal role in supporting tumor growth and transformed cells' survival. Recent data demonstrated that a chronic inflammatory condition persists, involving an innovative way of communication among tumor cells and accessory cells: the release of a class of extracellular vesicles (EVs) named exosomes. Exosomes are small vesicles components of the total circulome, carrying a wide range of molecules, such as proteins, DNA, RNA, miRNAs, and cytokines, based on the cell of origin. In course of the diseases, exosomes contact target cells, near or far, and pour out in these cells their content, modifying phenotype or intracellular pathway, resulting in pro-survival stimuli for tumor cells.
The aim of this Research Topic is to describe how this well-regulated crosstalk between transformed cells and tumor microenvironment improves the progression and survival of the tumor cells, including the role of tumor circulome as a predictor of diagnosis and prognosis, in the field of new molecular drug discovery.
We welcome contributions of different types of articles including original research articles, hypotheses, and theory, as well as reviews and mini-reviews, in particular, the following themes:
• Role of tumor microenvironment in tumor lymphocytes supporting
• Targeting of circulome and exosomes released by lymphoid cells and tumor microenvironment cells for the identification of novel biomarkers
• Perspective in pharmacological targeting of exosomes for diagnosis and treatment of lymphoid cells pathologies.